Insilico Medicine
Insilico Medicine applies generative AI to drug discovery through its Pharma.ai suite, including PandaOmics, Chemistry42 and inClinico, alongside its own drug pipeline.
About
Insilico Medicine develops generative AI and automation software for drug discovery, scientific research and sustainability. Its Pharma.ai suite covers target discovery with PandaOmics, molecule generation with Chemistry42, clinical trial prediction with inClinico, the DORA multi-agent research assistant, and the Nach01 foundation model. The company also runs more than 20 internal drug programs in cancer, inflammatory, metabolic and respiratory disease, and has out-licensed programs to partners such as Exelixis and Menarini.
- Organization type
- ai company
- Headquarters region
- Cambridge
- Founded
- Not stated
- Listings in the graph
- 0
- Last updated
- 6 October 2026
- Published
- 6 October 2026
Data sources & provenance
Where this information came from, how it was checked and when it was last looked at. “Last updated” records a change to the record — it does not mean the record was verified.
- Data quality
- Data quality: Editorially Reviewed
- Primary source
- insilico.com
- Sources cited
- 2
- Last reviewed
- 6 October 2026
- Last updated
- 6 October 2026
Spotted something out of date?
Anyone can suggest a correction — you don't need an account. An editor checks every suggestion against the sources before the record changes.
Products & technologies
No published products from this organization yet.
Services
No published services from this organization yet.
News & insights from this region
No related coverage published yet.
Events in this region
No related events published yet.
Learning resources
No learning resources from this provider yet.
Is this your organization?
Claim this profile to keep the description, products and services accurate, or add an organization that is missing from the graph.